Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Publication | Closed Access

DOI

1.8K

Citations

References

2016

Year

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma,

The Lancet Oncology

Breast OncologyHealth SciencesMedicinePharmacologyClinical TrialsGynecologyPalbociclib VersusBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyEndocrine-related CancerPhase 3Final Analysis